Biotech Growth sells Amgen, buys Regeneron and Alexion in March OrbiMed-managed Biotech Growth Trust (BIOG) sold a large proportion of its stake in Amgen last month, while increasing its holdings in Regeneron and Alexion, according to an analysis of its top holdings disclosed in its latest factsheet. The shareholding in Amgen, which accounted for just over 10% of […]
WWH’s hedging of Merck-BMS data comp backfires Worldwide Healthcare Trust’s (WWH) apparent attempt to hedge its bet on the outcome of the three trials of anti-pd(L)-1 checkpoint inhibitors in first-line treatment of non-small cell lung cancer that were reported simultaneously yesterday appears to have backfired, after the stock market determined the data justified an asymmetric response. […]
Shire disposal leaves BB Healthcare stake in limbo Shire Pharmaceuticals’ announcement this morning of an agreement to sell its oncology business to Servier for $2.4bn in cash, leaves the stake in the company held by BB Healthcare Trust (BBH) – the only sector specialist investment trust to have significant exposure – in limbo. This is because […]
BG-backed Orchard buys GSK rare disease portfolio Baillie Gifford-backed gene therapy company Orchard Therapeutics has acquired GlaxoSmithKline’s portfolio of investigational and approved rare disease gene therapies in exchange for a 19.9% equity stake as well as undisclosed milestones and royalties on sales. The acquired product portfolio includes Strimvelis, GSK’s EU-approved gene therapy for children with adenosine deaminase severe […]
Worldwide Health offers a way to play AACR lung data reveal London-listed Worldwide Healthcare Trust (WWH) could be best way for trust investors to obtain exposure to what is likely to be the most important clinical data disclosure involving large cap pharmaceutical companies this year. This is set to occur next Monday (16 April) at the American Association […]
BB Biotech may have to take hit on Incyte stake Switzerland’s BB Biotech (BBB.S) looks set to be in for a difficult month in terms of performance as a result of the negative result reported in a Phase III trial of a drug from Incyte Pharmaceuticals (Nasdaq:INCY), which was the trust’s third largest holding accounting […]
Syncona sees slight dip in NAV as Nightstar declines UK hybrid biotech investor/fund-of-funds Syncona (SYNC) saw a 0.8% fall in its NAV in February according to its latest factsheet, principally as a result of an 8% decline in the value of its holding in US-listed Nightstar Therapeutics. Syncona holds a 42% stake in this Nasdaq-quoted, but UK […]
WPCT gets surprise boost up trust leaguetable from Prothena deal An unexpected recovery in Woodford Patient Capital Trust (WPCT)’s share price last month on the back of the collaboration signed between investee Prothena (NASDAQ:PRTA) and Celgene (NASDAQ:CELG), has made the struggling investment trust the surprise top performer among the sector specialist funds in March, albeit amid […]
Trust favourite Alnylam sees shares tank on competitor success US RNAi therapeutic specialist Alnylam Pharmaceuticals (Nasdaq:ALNY) has seen its shares fall by 22% over the long Easter weekend, principally on news of a surprise positive clinical trial result for a potential competitor to its lead product patisiran, which has been developed initially for hereditary transthyretin-mediated amyloidosis […]
HBM Healthcare to benefit from Homology Medicines IPO Swiss-listed HBM Healthcare (HBMN) is set to receive a modest boost to its NAV following the US initial public offering last week of Homology Medicines (Nasdaq: FIXX), a US gene editing/gene therapy company developing treatments for rare disease. Homology raised a total of $165.6m from an offering of 10.35m shares at $16.00 […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated